Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117424) titled 'Study on the Effect of Coenzyme Q10 Intervention on Cardiac Toxicity Induced by Osimertinib' on Jan. 23.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Wenzhou Medical University
Condition:
Cardiovascular disease caused by coenzyme Q10 in patients with non-small cell lung cancer
Intervention:
ARB drugs group:N/A
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-30
Target Sample Size: ARB drugs group:10;ARB drugs + Coenzyme Q10 Group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.or...